Biogen’s headquarters in Cambridge, Massachusetts.Photo: Dominick Reuter (Getty Images) On Friday, the pharmaceutical company Biogen announced the Food and Drug Administration accepted its request to conduct a priority review of its experimental Alzheimer’s drug for approval. The faster-than-normal process sets the stage for treatment, called aducanumab, to be the first …
Read More »